• Cronos Group (CRON) and Gingko Biworks have achieved the productivity target for cannabigerolic acid (CBGA)
  • This is the first target productivity milestone in which the partnership will produce eight cultured cannabinoids
  • The milestone lays the foundation for Cronos’ planned CBGA product launch sometime this fall
  • Cronos Group and Gingko initially entered the partnership in 2018 with the goal of accessing rare molecules in the cannabis plant with plans to develop eight molecules
  • Shares of Cronos Group are up 1.39 per cent to C$8.01 as of 12:11 p.m. EDT

Cronos Group (CRON) and its partner Gingko Bioworks have announced they have achieved the productivity target for cannabigerolic acid (CBGA).

This is the first target productivity milestone in which the partnership’s goal is to produce eight cultured cannabinoids.

Through Gingko’s platform for organism design and development, Cronos Group has been able to achieve the productivity target for CBGA, which will act as the backdrop for Cronos’ CBG product launch sometime this fall.

“Cronos Group and Ginkgo are uniquely positioned to elevate the cannabis industry through cannabinoid and product innovation to unlock the next generation of its potential,” Kurt Schmidt, president and CEO of Cronos Group, said in a press release. “Ginkgo’s platform enables companies across a multitude of industries to reach their customers with better products. We are proud to use our combined capabilities to make the benefits of cannabinoids more accessible to consumers.”

The companies entered into the partnership in 2018 with the goal of accessing rare molecules in the cannabis plant and developing eight molecules.

“We’re thrilled to see the progress our partnership with Cronos Group has made in the three years we have been working together and consider it a demonstration of how much can be accomplished when a leading-edge company applies our platform,” Jason Kelly, CEO of Gingko Bioworks, said in the release.

Following the achievement of the final productivity target for CBGA, Cronos Group will issue a milestone payment of roughly 1.5 million common shares to Gingko.

Shares of Cronos Group are up 1.39 per cent to C$8.01 as of 12:11 p.m. EDT.

More From The Market Online
Cannabis Report across cannabis plants

StockTalk | Cannabis Report: Shake-ups

MediPharm Labs announced that chief executive officer, David Pidduck will step down from his role, effective January...

Buzz on the Bullboards: As Arctic tensions flare, investors eye three news‑making stocks

Global markets opened the week on edge as a fresh rift between Washington and key NATO...

MediPharm Labs announces CEO transition as David Pidduck steps down

MediPharm Labs (TSX:LABS) CEO David Pidduck will step down on January 23, 2026, and will remain on the Board to support the transition.
Cannabis leaves with Stock Talk and Cannabis Report labels

StockTalk | Cannabis Report: New digs

Cannabis e-commerce company Herbal Dispatch (CSE:HERB) grew sales by 38 per cent in 2025, marking its third-straight year...